Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

High-throughput Screening in Larval Zebrafish Identifies Novel Potent Sedative-hypnotics.

Yang X, Jounaidi Y, Dai JB, Marte-Oquendo F, Halpin ES, Brown LE, Trilles R, Xu W, Daigle R, Yu B, Schaus SE, Porco JA Jr, Forman SA.

Anesthesiology. 2018 Jun 12. doi: 10.1097/ALN.0000000000002281. [Epub ahead of print]

PMID:
29894316
2.

Combining Mutations and Electrophysiology to Map Anesthetic Sites on Ligand-Gated Ion Channels.

Forman SA.

Methods Enzymol. 2018;602:369-389. doi: 10.1016/bs.mie.2018.01.014. Epub 2018 Feb 28.

PMID:
29588039
3.

Comparison of αβδ and αβγ GABAA receptors: Allosteric modulation and identification of subunit arrangement by site-selective general anesthetics.

Feng HJ, Forman SA.

Pharmacol Res. 2018 Jul;133:289-300. doi: 10.1016/j.phrs.2017.12.031. Epub 2017 Dec 30. Review.

PMID:
29294355
4.

Alphaxalone Binds in Inner Transmembrane β+-α- Interfaces of α1β3γ2 γ-Aminobutyric Acid Type A Receptors.

Ziemba AM, Szabo A, Pierce DW, Haburcak M, Stern AT, Nourmahnad A, Halpin ES, Forman SA.

Anesthesiology. 2018 Feb;128(2):338-351. doi: 10.1097/ALN.0000000000001978.

PMID:
29210709
5.

Propofol Is an Allosteric Agonist with Multiple Binding Sites on Concatemeric Ternary GABAA Receptors.

Shin DJ, Germann AL, Johnson AD, Forman SA, Steinbach JH, Akk G.

Mol Pharmacol. 2018 Feb;93(2):178-189. doi: 10.1124/mol.117.110403. Epub 2017 Nov 30.

PMID:
29192122
6.

Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.

Jounaidi Y, Cotten JF, Miller KW, Forman SA.

Cancer Res. 2017 Nov 1;77(21):5938-5951. doi: 10.1158/0008-5472.CAN-17-1007. Epub 2017 Sep 15.

PMID:
28916655
7.

Synthesis and pharmacological evaluation of neurosteroid photoaffinity ligands.

Savechenkov PY, Chiara DC, Desai R, Stern AT, Zhou X, Ziemba AM, Szabo AL, Zhang Y, Cohen JB, Forman SA, Miller KW, Bruzik KS.

Eur J Med Chem. 2017 Aug 18;136:334-347. doi: 10.1016/j.ejmech.2017.04.043. Epub 2017 Apr 21.

PMID:
28505538
9.
10.

Novel positive allosteric modulators of GABAA receptors with anesthetic activity.

Maldifassi MC, Baur R, Pierce D, Nourmahnad A, Forman SA, Sigel E.

Sci Rep. 2016 May 20;6:25943. doi: 10.1038/srep25943.

11.

Correction for Inhibition Leads to an Allosteric Co-Agonist Model for Pentobarbital Modulation and Activation of α1β3γ2L GABAA Receptors.

Ziemba AM, Forman SA.

PLoS One. 2016 Apr 25;11(4):e0154031. doi: 10.1371/journal.pone.0154031. eCollection 2016.

12.
13.

Contrasting actions of a convulsant barbiturate and its anticonvulsant enantiomer on the α1 β3 γ2L GABAA receptor account for their in vivo effects.

Desai R, Savechenkov PY, Zolkowska D, Ge RL, Rogawski MA, Bruzik KS, Forman SA, Raines DE, Miller KW.

J Physiol. 2015 Nov 15;593(22):4943-61. doi: 10.1113/JP270971.

14.

Etomidate uniquely modulates the desensitization of recombinant α1β3δ GABA(A) receptors.

Liu K, Jounaidi Y, Forman SA, Feng HJ.

Neuroscience. 2015 Aug 6;300:307-13. doi: 10.1016/j.neuroscience.2015.05.051. Epub 2015 May 29.

15.

Fluoxetine prevents respiratory arrest without enhancing ventilation in DBA/1 mice.

Zeng C, Long X, Cotten JF, Forman SA, Solt K, Faingold CL, Feng HJ.

Epilepsy Behav. 2015 Apr;45:1-7. doi: 10.1016/j.yebeh.2015.02.013. Epub 2015 Mar 13.

16.

Mutations at beta N265 in γ-aminobutyric acid type A receptors alter both binding affinity and efficacy of potent anesthetics.

Stewart DS, Pierce DW, Hotta M, Stern AT, Forman SA.

PLoS One. 2014 Oct 27;9(10):e111470. doi: 10.1371/journal.pone.0111470. eCollection 2014.

17.

Anesthetics target interfacial transmembrane sites in nicotinic acetylcholine receptors.

Forman SA, Chiara DC, Miller KW.

Neuropharmacology. 2015 Sep;96(Pt B):169-77. doi: 10.1016/j.neuropharm.2014.10.002. Epub 2014 Oct 12. Review.

18.

Research at the Harvard Anesthesia Departments.

Forman SA, Miller KW, Talmor D, Hickey P, Strichartz G, Wiener-Kronish J.

Anesthesiology. 2014 Dec;121(6):1141-3. doi: 10.1097/ALN.0000000000000483. No abstract available.

19.

Human α1β3γ2L gamma-aminobutyric acid type A receptors: High-level production and purification in a functional state.

Dostalova Z, Zhou X, Liu A, Zhang X, Zhang Y, Desai R, Forman SA, Miller KW.

Protein Sci. 2014 Feb;23(2):157-66. doi: 10.1002/pro.2401. Epub 2013 Dec 16.

20.

Etomidate produces similar allosteric modulation in α1β3δ and α1β3γ2L GABA(A) receptors.

Feng HJ, Jounaidi Y, Haburcak M, Yang X, Forman SA.

Br J Pharmacol. 2014 Feb;171(3):789-98. doi: 10.1111/bph.12507.

21.

In reply.

Forman SA.

Anesthesiology. 2013 Oct;119(4):996. doi: 10.1097/ALN.0b013e3182a46271. No abstract available.

PMID:
24195888
22.

Cysteine substitutions define etomidate binding and gating linkages in the α-M1 domain of γ-aminobutyric acid type A (GABAA) receptors.

Stewart DS, Hotta M, Li GD, Desai R, Chiara DC, Olsen RW, Forman SA.

J Biol Chem. 2013 Oct 18;288(42):30373-86. doi: 10.1074/jbc.M113.494583. Epub 2013 Sep 5.

23.

Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT).

Overgaard CB, Džavík V, Buller CE, Liu L, Banasiak W, Devlin G, Maggioni AP, Leor J, Burton JR, Reis G, Ruzyllo W, Forman SA, Lamas GA, Hochman JS; OAT Investigators.

Int J Cardiol. 2013 Oct 3;168(3):2416-22. doi: 10.1016/j.ijcard.2013.02.004. Epub 2013 Apr 10.

PMID:
23582414
24.

State-dependent etomidate occupancy of its allosteric agonist sites measured in a cysteine-substituted GABAA receptor.

Stewart DS, Hotta M, Desai R, Forman SA.

Mol Pharmacol. 2013 Jun;83(6):1200-8. doi: 10.1124/mol.112.084558. Epub 2013 Mar 22.

25.

A paradigm shift from biophysical to neurobiological: the fading influence of Claude Bernard's ideas about general anesthesia.

Forman SA.

Anesthesiology. 2013 Apr;118(4):984-5. doi: 10.1097/ALN.0b013e3182860777. No abstract available.

26.

The expanding genetic toolkit for exploring mechanisms of general anesthesia.

Forman SA.

Anesthesiology. 2013 Apr;118(4):769-71. doi: 10.1097/ALN.0b013e318287b7e4. No abstract available.

27.

Infarct artery distribution and clinical outcomes in occluded artery trial subjects presenting with non-ST-segment elevation myocardial infarction (from the long-term follow-up of Occluded Artery Trial [OAT]).

Menon V, Ruzyllo W, Carvalho AC, Almeida de Sousa JM, Forman SA, Jaworska K, Lamas GA, Roik M, Thuaire C, Turgeman Y, Hochman JS.

Am J Cardiol. 2013 Apr 1;111(7):930-5. doi: 10.1016/j.amjcard.2012.12.009. Epub 2013 Jan 22.

28.

Heart failure in post-MI patients with persistent IRA occlusion: prevalence, risk factors, and the long-term effect of PCI in the Occluded Artery Trial (OAT).

Jhaveri RR, Reynolds HR, Katz SD, Jeger R, Zinka E, Forman SA, Lamas GA, Hochman JS.

J Card Fail. 2012 Nov;18(11):813-21. doi: 10.1016/j.cardfail.2012.10.012.

29.

Azo-propofols: photochromic potentiators of GABA(A) receptors.

Stein M, Middendorp SJ, Carta V, Pejo E, Raines DE, Forman SA, Sigel E, Trauner D.

Angew Chem Int Ed Engl. 2012 Oct 15;51(42):10500-4. doi: 10.1002/anie.201205475. Epub 2012 Sep 11.

30.

Allyl m-trifluoromethyldiazirine mephobarbital: an unusually potent enantioselective and photoreactive barbiturate general anesthetic.

Savechenkov PY, Zhang X, Chiara DC, Stewart DS, Ge R, Zhou X, Raines DE, Cohen JB, Forman SA, Miller KW, Bruzik KS.

J Med Chem. 2012 Jul 26;55(14):6554-65. doi: 10.1021/jm300631e. Epub 2012 Jul 17.

31.

Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Hastings RS, Hochman JS, Dzavik V, Lamas GA, Forman SA, Schiele F, Michalis LK, Nikas D, Jaroch J, Reynolds HR.

Am J Cardiol. 2012 Oct 1;110(7):954-60. doi: 10.1016/j.amjcard.2012.05.024. Epub 2012 Jun 22.

32.

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT).

Freixa X, Džavík V, Forman SA, Rankin JM, Buller CE, Cantor WJ, Ruzyllo W, Reynolds HR, Lamas GA, Hochman JS.

Am Heart J. 2012 Jun;163(6):1011-8. doi: 10.1016/j.ahj.2012.03.008. Erratum in: Am Heart J. 2013 Apr;165(4):638.

33.

Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate.

Forman SA.

Curr Opin Anaesthesiol. 2012 Aug;25(4):411-8. doi: 10.1097/ACO.0b013e328354feea. Review.

34.

Carboetomidate inhibits alpha4/beta2 neuronal nicotinic acetylcholine receptors at concentrations affecting animals.

Pierce DW, Pejo E, Raines DE, Forman SA.

Anesth Analg. 2012 Jul;115(1):70-2. doi: 10.1213/ANE.0b013e318254273e. Epub 2012 Apr 27.

35.

Two etomidate sites in α1β2γ2 γ-aminobutyric acid type A receptors contribute equally and noncooperatively to modulation of channel gating.

Guitchounts G, Stewart DS, Forman SA.

Anesthesiology. 2012 Jun;116(6):1235-44. doi: 10.1097/ALN.0b013e3182567df3.

36.

Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT).

Reynolds HR, Forman SA, Tamis-Holland JE, Steg PG, Mark DB, Pearte CA, Carvalho AC, Sopko G, Liu L, Lamas GA, Kruk M, Loboz-Grudzien K, Ruzyllo W, Hochman JS.

Am Heart J. 2012 Mar;163(3):462-9. doi: 10.1016/j.ahj.2012.01.005.

37.

Comparison of late results of percutaneous coronary intervention among stable patients ≤65 versus >65 years of age with an occluded infarct related artery (from the Occluded Artery Trial).

Skolnick AH, Reynolds HR, White HD, Menon V, Carvalho AC, Maggioni AP, Pearte CA, Gruberg L, Azevedo RE, Schroeder E, Forman SA, Lamas GA, Hochman JS, Džavík V.

Am J Cardiol. 2012 Mar 1;109(5):614-9. doi: 10.1016/j.amjcard.2011.10.015. Epub 2011 Dec 14.

38.

An allosteric coagonist model for propofol effects on α1β2γ2L γ-aminobutyric acid type A receptors.

Ruesch D, Neumann E, Wulf H, Forman SA.

Anesthesiology. 2012 Jan;116(1):47-55. doi: 10.1097/ALN.0b013e31823d0c36.

39.

Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite.

Ge RL, Pejo E, Haburcak M, Husain SS, Forman SA, Raines DE.

Anesth Analg. 2012 Aug;115(2):305-8. doi: 10.1213/ANE.0b013e318239c6ca. Epub 2011 Nov 3.

40.

Mutations in the GABAA receptor that mimic the allosteric ligand etomidate.

Forman SA, Stewart D.

Methods Mol Biol. 2012;796:317-33. doi: 10.1007/978-1-61779-334-9_17.

41.

p-(4-Azipentyl)propofol: a potent photoreactive general anesthetic derivative of propofol.

Stewart DS, Savechenkov PY, Dostalova Z, Chiara DC, Ge R, Raines DE, Cohen JB, Forman SA, Bruzik KS, Miller KW.

J Med Chem. 2011 Dec 8;54(23):8124-35. doi: 10.1021/jm200943f. Epub 2011 Nov 10.

42.

Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.

Hochman JS, Reynolds HR, Dzavík V, Buller CE, Ruzyllo W, Sadowski ZP, Maggioni AP, Carvalho AC, Rankin JM, White HD, Goldberg S, Forman SA, Mark DB, Lamas GA; Occluded Artery Trial Investigators.

Circulation. 2011 Nov 22;124(21):2320-8. doi: 10.1161/CIRCULATIONAHA.111.041749. Epub 2011 Oct 24.

43.

Dr. Joseph Warren: physician founder and true Tea Partyer.

Forman SA.

Endocr Pract. 2011 Jul-Aug;17(4):662-4. No abstract available.

PMID:
21846622
44.

The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone.

Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Kufera JA, Forman SA, Teresinska A, Bychowiec B, Marin-Neto JA, Höchtl T, Cohen EA, Caramori P, Busz-Papiez B, Adlbrecht C, Sadowski ZP, Ruzyllo W, Kinan DJ, Lamas GA, Hochman JS.

Am Heart J. 2011 Mar;161(3):611-21. doi: 10.1016/j.ahj.2010.11.020.

45.

Clinical and molecular pharmacology of etomidate.

Forman SA.

Anesthesiology. 2011 Mar;114(3):695-707. doi: 10.1097/ALN.0b013e3181ff72b5. Review.

46.

Anesthetic sites and allosteric mechanisms of action on Cys-loop ligand-gated ion channels.

Forman SA, Miller KW.

Can J Anaesth. 2011 Feb;58(2):191-205. doi: 10.1007/s12630-010-9419-9. Epub 2011 Jan 7. Review.

47.

Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT).

Devlin G, Reynolds HR, Mark DB, Rankin JM, Carvalho AC, Vozzi C, Sopko G, Caramori P, Džavík V, Ragosta M, Forman SA, Lamas GA, Hochman JS.

Am Heart J. 2011 Jan;161(1):84-90. doi: 10.1016/j.ahj.2010.09.009.

48.

Molecular approaches to improving general anesthetics.

Forman SA.

Anesthesiol Clin. 2010 Dec;28(4):761-71. doi: 10.1016/j.anclin.2010.08.004. Review.

49.

Iatrogenic risk factors for Alzheimer's disease: surgery and anesthesia.

Vanderweyde T, Bednar MM, Forman SA, Wolozin B.

J Alzheimers Dis. 2010;22 Suppl 3:91-104. doi: 10.3233/JAD-2010-100843. Review.

50.

p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.

Husain SS, Stewart D, Desai R, Hamouda AK, Li SG, Kelly E, Dostalova Z, Zhou X, Cotten JF, Raines DE, Olsen RW, Cohen JB, Forman SA, Miller KW.

J Med Chem. 2010 Sep 9;53(17):6432-44. doi: 10.1021/jm100498u.

Supplemental Content

Loading ...
Support Center